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A B S T R A C T
Purpose: This study aims to investigatem-calpain expression proﬁles in the anterior temporal neocortex
in patients with intractable epilepsy, and to determine whether its pattern of expression is related to
pathological changes seen in these patients.
Methods: The study subjects consisted of 30 patients with intractable epilepsy and a control group of 10
patients with brain trauma who underwent resection of the anterior temporal lobe. m-Calpain
expression in surgically resected anterior temporal cortices of patients with intractable epilepsy were
analyzed using the RT-PCR, Western blot, immnohistochemistry and immunoﬂuorescence staining.
GFAP expression was detected by immunohistochemical staining. The related pro-inﬂammatory
cytokines were quantiﬁed by elisa. Clinicopathological characteristics were evaluated by HE staining.
Results: Analysis by Western blot and RT-PCR revealed that inactive m-calpain expression and the
calpain-cleaved spectrin fragment in surgically resected anterior temporal cortices of patients with
intractable epilepsy were signiﬁcantly increased compared to the tissues from corresponding regions of
the control group. Immunohistological staining demonstrated that m-calpain was overexpressed in the
cell cytoplasm of neurons and glial cells in patients with intractable epilepsy and GFAP was
overexpressed in the cell cytoplasm of glial cells in patients with intractable epilepsy. The level of pro-
inﬂammatory cytokines, such as IL-1b, IL-6 and TGF-b1 were signiﬁcantly increased in patients with
intractable epilepsy. HE staining indicatedm-calpain overexpression is an independent prognostic factor
for pathological changes such as neuronal loss, neuronal degeneration, gliosis and astrocytosis.
Conclusion: These data suggest that overexpression ofm-calpain is relationshipwith intractable epilepsy
as well as the clinicopathological characteristics in these patients.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a common devastating neurological condition.
Although 80% of epileptic patients are seizure-free with rational
anti-epileptic drug (AED) therapy, approximately 20% of patients
with epilepsy have a medically intractable condition even when
treated with various AEDs at maximal dosages, either alone or in
combination.1 Such epilepsy cases are, thus, referred to as
intractable epilepsy (IE).
Recurrent seizures may cause necrosis within certain cell
populations.2,3 Studies have also identiﬁed upregulation of bcl-2
family genes, including Bcl-2, Bcl-XL and activated caspase 3 in* Corresponding author. Tel.: +86 23 68708697; fax: +86 23 89014008.
E-mail address: proyanyong@126.com (Y. Yan).
1 The authors contributed equally in this work.
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.010temporal neocortices from patients with temporal lobe epilepsy
(TLE).4,5 Therefore, the bcl-2 and caspase families, which regulate
cell death, may play a role in ongoing neuropathologic processes in
human epilepsy.6 Further, more recent works have shown that
increased Bax expression and activated caspases contribute to
neuronal loss through apoptosis.7
Calpains, a class of Ca2+-activated cysteine proteases, are major
mediators for Ca2+ signals in many biological systems. There are
two subtypes of calpains: I or m-calpain and II or m-calpain; m-
calpain is the predominant type found in tissues, including
neocortex.8 Calpains are proposed to participate in the turnover
of cytoskeletal proteins and regulate kinases, cytokine,transcrip-
tion factors and receptors.9
Pathological activation of calpain results in the cleavage of
numerous neuronal substrates that negatively affect neuronal
structure and function, thereby, leading to inhibition of essential
neuronal survival mechanisms. Indeed, many proteins have beenvier Ltd. All rights reserved.
Table 1
Patient characteristics.
Total (n=30)
Age (years) 24.069.42
Gender (n)
Male 16
Female 14
Onset of seizure (n)
<18 years 20
18 years 10
Course of epilepsy (n)
<10 years 18
10 years 12
Frequency of seizures per month (n)
3–4 5
4–8 15
>8 10
Family history of epilepsy (n)
Yes 3
No 27
MRIa (n)
Abnormal 13
Normal 17
Patterns of seizures (n)
Complex focal seizures 10
Generalized tonic–clonic seizure 4
Tonic spasm 3
Secondary generalized seizure 7
Multiple seizure patterns 6
Values are means SEM, or number.
a Normal means no structural abnormality of brain, and abnormal MRI means
hippocampal sclerosis, focal cortical dysplasia and temporal lobe malacia, multiple
seizure patterns include simplex partial seizure, complex partial seizure and
secondarily generalized seizure.
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and Bcl-xL.10 Moreover, activated calpain mediates the degrada-
tion of calpain substrates in the course of neuronal death and
contributes to the pathophysiology of neurological disorders, such
as ischemia, trauma, Alzheimer’s disease and demyelination.11–14
Bi et al. (1997) ﬁrst reported the effect of calpain activation in
animal models of epilepsy and, essentially, found a high degree of
calpain expression.15 Further evidence for increased calpain
activity has been described in the hippocampus of rodent models
of temporal lobe epilepsy.16 Later, Araujo et al. investigated the
activation of calpains and caspases in degenerating areas of the
hippocampus, as well as the proteolysis of known substrates
[spectrin, for calpains, and poly-ADP ribose polymerase (PARP) for
caspase 3] in the hippocampus of rats given kainic acid (KA)
systemically. They found that early calpain activation, but not
caspase activation, is involved in neurotoxicity in the hippocampus
after status epilepticus; calpain inhibition was strongly correlated
with neurodegeneration in the hippocampus following seizures.16
Calpain-mediated mechanisms may be responsible for seizure
offset, probably through AMPA glutamate receptor internalization
and further degradation.17 Little information, however, is currently
available concerning the role of calpains in intractable epilepsy.
Therefore, we investigated the expression of m-calpain in patients
with intractable epilepsy and its correlation with clinicopatholog-
ical characteristics.
2. Materials and methods
2.1. Patients selection
Intractable seizures were deﬁned as those not controlled in all
patients bymaximal tolerated doses of at least two AEDs, including
phenytoin, valproic acid, carbamazepine, phenobarbital, topira-
mate, oxcarbazepine, clonazepam, gabapentin and lamotrigine. A
total of 30 patients with intractable epilepsy were recruited from
the ﬁles of the department of neurosurgery of the following
hospitals: The First Afﬁliated Hospital of Chongqing Medical
University and Xinqiao Hospital of the Third Military Medical
University. All of these patients underwent resection of the
anterior temporal lobe. The diagnosis of epilepsy was determined
according to the 1981 International Classiﬁcation of Epileptic
Seizures by the International League Against Epilepsy. Prior to
surgery, the lesion was localized in all patients via several
methods, including brain magnetic resonance imaging, a 24-h
electroencephalogram or video electroencephalogram, sphenoidal
electrode monitoring, and intraoperative electrocorticography.
Table 1 summarizes the clinical features of the patients.
The control group consisted of temporal lobe samples obtained
from 10 patients who underwent neurosurgical intervention due
to brain trauma in the Neurosurgical Department of The First
Afﬁliated Hospital of Chongqing Medical University. All controls
were diagnosed as brain trauma, and neuropathologists found no
abnormality in the specimen slides of these control patients. Table
2 shows the clinical features of the controls.
The study was approved by the ethics committee on human
research at Chongqing Medical University. Informed consent was
obtained from the patients or their relatives for the use of any data
and tissues for research, which was performed in accordance with
the Helsinki Declaration.
2.2. RT-PCR
cDNA equivalent to 20 ng of total RNA was subjected to
subsequent semi-quantiﬁed PCR analysis using the following
primers: CAPN1 (sense, TCG TGC TCG CCC TTA TGC; antisense,
CTT GTC CAG GTC AAA CTT CC), and GAPDH (sense, ATC TGG CACCAC ACC TTC TAC A; anti-sense, GTT TGG TGG ATG CCA CAGGAC T).
In preliminary experiments, optimal cycling conditions were
established for ampliﬁcation of each cDNA. PCR products were
separated on1.5%agarosegel containing10 g/ml ethidiumbromide,
photographed using the UVsolo system (Whatman Biometra) and
densitometric analysis was performed with the BioDocAnalyze
software (WhatmanBiometra). Resultswere calculated according to
levels of targetmRNAs in relation to thoseof the housekeeping gene,
GAPDH (three samples from each group were analyzed by PCR).
2.3. Western blotting
Tissues were homogenized and lysed in Laemmli buffer. The
protein concentration of the lysates was determined using a
Coomassie blue G-250 kit (Sigma, St. Louis, USA). The protein
extracts (50mg) were resolved by 10% SDS polyacrylamide gel
electrophoresis and electrotransferred to a polyvinylidene diﬂuor-
ide (PVDF) membrane (Dupont,Wilmington, USA). The membranes
were blocked with 3% BSA (Sigma) and then incubated for 2 h at
room temperature in PBS. After extensive washing with phosphate
buffered saline (PBS), the membranes were incubated with the
following primary antibodies: rabbit anti-humanm-calpain (1:200;
Santa Cruz Biotechnology), 145 kDa a-spectrin speciﬁc antibody
(1:200; Santa Cruz Biotechnology), and monoclonal anti-GAPDH
(Santa Cruz Biotechnology) at a dilution of 1:1000 for 1 h. Goat anti-
rabbit HPRIgG (1:5000; Sigma) was used for detection. Subsequent-
ly, the protein bands were visualized after exposure to ﬁlm and the
pixel density of the scanned ﬁlm images was quantiﬁed using
Labworks Analysis Software (UVP, Upland, USA). Western blot data
were normalized relative to the density of the GAPDH bands.
2.4. Cytokine quantiﬁcation
The overall cytokine levels in the anterior temporal lobe were
measured by the Multi-Analyte ELISA array Kit (SA Biosciences,
Table 2
Patient characteristics.
Patient no. Gender/age (Y) Clinical diagnosis Source of tissues Region of tissues Adjacent tissue pathology
1 15, M Trauma Surgical specimen TNr, PCr No particular ﬁndings
2 26, F Trauma Surgical specimen TNI No particular ﬁndings
3 42, M Brain tumor Surgical specimen TNI No particular ﬁndings
4 20, M Trauma Surgical specimen TNr, FCr No particular ﬁndings
5 22, F Trauma Surgical specimen TNr No particular ﬁndings
6 16, M Trauma Surgical specimen TNI, HI No particular ﬁndings
7 27, M Trauma Surgical specimen TNr, PCr No particular ﬁndings
8 31, F Trauma Surgical specimen TNI No particular ﬁndings
9 17, M Trauma Surgical specimen TNr, Hr No particular ﬁndings
10 33, F Brain tumor Surgical specimen TNr No particular ﬁndings
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anterior temporal lobe using the Halt Protease Inhibitor Cocktail
Kit (Pierce), centrifuged at 78,500  g for one 1 h at 4 8C, and were
collected and stored at -70 8C until assayed. According to the kit’s
manual instructions, the levels of 12 cytokines and chemokines (IL-
1b, IL-6, IL-10, IL-12, IL-17a, IFN-g, TNF-a and TGF-b1) were
detected simultaneously at 1:20 dilutions. Negative and positive
controls supplied by the kits were also included. The reactions
were analyzed at a wavelength of 450 nm using a 96-well
microplate reader, Model 680 (Bio-Rad, Hercules, CA, USA).
2.5. Hematoxylin-eosin
The resected brain tissue was immediatedly ﬁxed in 10%
buffered formalin. After ﬁxation in formalin for 48 h, the parafﬁn-
embedded tissue was sectioned into 10 mm slices for immunohis-
tochemistry and immunoﬂuorescence analysis, and then mounted
onto polylysine-coated slides. One section of each specimen was
processed for hematoxylin-eosin staining. Control samples were
prepared in the same way. Surgical specimens, sectioned with a
microtome and stained with hematoxylin-eosin, were submitted
for neuropathological evalution..
2.6. Immunohistochemistry
The procedure was performed according to the manufacturer’s
protocol. First, parafﬁn sections were deparafﬁnized, hydrated
through a graded ethanol series and incubated in 0.3% H2O2 for
15 min. The sections were heated in a microwave oven for 10 min
at 98 8C in citrate buffer (pH 6) for antigen retrieval, and blocked in[()TD$FIG]Fig. 1. Calpain was overexpressed in the anterior temporal neocortex of patients with in
control and the epileptic human samples by semi-quantitative RT-PCR of mRNA levels. T
internal control. Densitometry analysis was performed using FluorChem software. The
expressed as mean  SD. The value of *p < 0.05 is indicated as signiﬁcantly different. (B) W
and a-spectrin (m-calpain-mediated breakdown of spectrin) in the control and the epilepti
SDS-PAGE for each sample and probed with the primary antibody of m-calpain. Densitome
qualitatively visualizingm-calpain expression levels. Histograms of the normalizedm-calpai
as mean  SD. The value of *p < 0.05 is indicated as signiﬁcantly different.normal goat serum (1:10; Zhongshan Golden Bridge Inc, Beijing,
China) for 10 min. The sections were incubated in the following
primary antibodies: primary rabbit anti-human m-calpain (1:150;
Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at 37 8C, primary
rabbit anti-human GFAP (1:200; Zhong shan Golden Bridge Inc,
China). Anti-rabbit secondary antibody was used for detection for
30 min at 37 8C. Immunoreactivity was observed with 3,30-
diaminobenzidine (Zhongshan Golden Bridge Inc.). The OLYMPUS
PM20 automatic microscope (Olympus, Osaka, Japan) and TC-FY-
2050 pathology system (Yuancheng Inc., Beijing, China) were used
to collect the images. Primary antibodies were replaced with PBS
(pH 7.2) and served as negative controls.
2.7. Immunoﬂuorescence
Sections were deparafﬁnized and antigen was recovered as
described in the previous section. Tissueswere permeabilizedwith
0.5% (v/v) Triton X-100. After blocking with 10% goat serum in PBS
for 30 min, followed by incubation with the following primary
antibodies: rabbit anti-human m-calpain (1:150) in PBS at 4 8C
overnight, rabbit antibody GFAP(1:200). Sections containing m-
calpain antibody were incubated with Alexa Fluor 488-conjugated
goat anti-rabbit IgG (H + L) (1:200, 10 mg/ml; green; Santa Cruz
Biotechnology) in PBS in the dark for 60 min at room temperature.
Sections containing GFAP antibody were incubated with tetra-
methylrhodamine isothiocyanate (TRITC)-conjugated goat anti-
rabbit IgG (1:200, 10 mg/ml; red; Zhong shan Golden Bridge Inc.,
Beijing, China). Fluorescence was detected by laser scanning
confocal microscopy (Leica Microsystems Heidelberg GmbH,
Heidelberg, Germany) on an Olympus IX 70 inverted microscopetractable epilepsy. (A) Identiﬁcation of the expression patterns of m-calpain in the
otal RNA was isolated from the anterior temporal neocortex. GAPDHwas used as an
intensity of bands was quantiﬁed and normalized by that of GAPDH. The data are
estern blot analysis was used to validate the differential displays for inactivem-calpain
c human samples. Total proteins (10 mg/lane) were extracted from human samples by
try analysis was performed using FluorChem software. Representative Western blots
n band intensities for the epileptic group and the control group. The data are expressed
[()TD$FIG]
Fig. 2. Calpain immunoreactivity in the temporal lobe of IE patients by immunohistochemical staining. (A) Faint positive staining in the control illustrates decreased m-
calpain expression. Strongly positive staining in the cortex of the temporal lobe of a patient with IE reﬂects increasedm-calpain expression (buffy particles in the cytoplasm of
neurons and glial cells). Scale bars = 100 mm. (B) Immunoﬂuorescence ofm-calpain expression in the control and patientswith temporal lobe epilepsy (TLE). Thewhite arrows
indicate positive cells (a: neuron; b: glial cell) representing increased m-calpain expression. Scale bars = 75mm. The data are expressed as mean  SD, and the value of
*p < 0.05 is indicated as signiﬁcantly different.
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densities for every sample were analyzed automatically and semi-
quantitatively using the Motic Med 6.0 CMIAS pathology image
analysis system (Beihang Motic, Inc., Beijing, China).
2.8. Statistical analysis
Data are represented as means  standard error of the mean
(SEM). Student’s t-test was used for statistical analysis with SPSS 11.0
between epileptic tissues and the control tissues. p Value of <0.05
was used as the minimum criteria for statistical signiﬁcance.
3. Results
3.1. Demographic and clinical characteristics of the epilepsy subjects
The mean age of the epilepsy patients was 24.06  9.42 years,
with 16 men and 14 women in the experimental group. The mean
duration of seizure recurrence was 8.93  4.06 years. The control
group consisted of 10 men and 9 women, with an average age of
24.90  8.65 years. Statistical analysis showed that there were no
signiﬁcant differences in age or sex between the IE patients and
controls (p > 0.05). 50% of patients had neuronal loss while 86.7% had
experienced seizure recurrence for at least 5 years, with 43.3% having
recurrences for more than 10 years.
3.2. m-Calpain was overexpressed in the anterior temporal neocortex
of patients with intractable epilepsy
The m-calpain gene was analyzed in epileptic tissues and
control tissues using semi-quantiﬁcation of RT-PCR products. The
expression of the m-calpain gene in the control group was
signiﬁcantly lower compared to the epilepsy group (Fig. 1A).
mRNA expression for m-calpain was measured by densitometric
evaluation of PCR results. GAPDH served as the internal control.
Values are expressed as mean SEM, with p < 0.05 considered
statistically signiﬁcant.
Protein expression of m-calpain in the controls as well as the
temporal lobes of IE patients, via Western blotting, indicate that
relatively strong expression of the inactive form of 80-kDa m-
calpain and a calpain-cleaved spectrin fragment of 145 kDa was
observed in the epileptic tissues, whereas faintly stained bands
were present in the control group samples (Fig. 1B). m-Calpainexpression was normalized by calculating the ratio of the optical
density of the bands form-calpain and GAPDH. The optical density
ratio was 0.5146  0.131 for epileptic tissues and 0.2756  0. 0.070
for control tissues; these values were signiﬁcantly different
(p < 0.05). Analysis of the calpain-cleaved 145 kDa spectrin fragment
expression in the control and the temporal lobe of IE patients by
Western blotting indicated that relatively strong expression of
145 kDa a-spectrin was observed in the epileptic tissues, whereas
faintly stained bands were present in the control group samples. The
optical density ratio was 0.4746  0.080 for epileptic tissues and
0.2056  0.0467 for control tissues; these values were signiﬁcantly
different (p < 0.05).
3.3. Immunohistochemical study of m-calpain expression and
localization in normal tissues and intractable epilepsy
Prominent m-calpain staining in the anterior temporal neocor-
tex of patients with IE correlates with positive expression of m-
calpain (buffy particles in the cytoplasm of neurons and glial cells),
and was observed in the temporal lobe cortices in both IE patients
and the control group using immunohistochemistry and immu-
noﬂuorescence staining (Fig. 2A and B). Positive staining for m-
calpain in this section is brown. There was signiﬁcantly stronger
m- calpain staining in epileptic temporal lobe tissues compared to
control. The mean optical densities for the IE group and control
group were 0.4124  0.039 and 0.2521  0.042, respectively. There
was signiﬁcantly higher expression ofm-calpain in the temporal lobe
cortex of the IE group compared to the control group (p < 0.05).
Immunoﬂuorescence shows positive staining for m-calpain in this
section as green. There was signiﬁcantly stronger m-calpain staining
in epileptic temporal lobe tissues compared to control. The mean
optical densities for the IE group and control group were
0.8236  0.102 and 0.4046  0.0910, respectively. There was signiﬁ-
cantly higher expression of m-calpain in the temporal lobe cortex of
the IE group compared to the control group (p <0.05).
3.4. GFAP was overexpressed in the cell cytoplasm of glial cells in
patients with intractable epilepsy
Prominent GFAP staining in the anterior temporal neocortex of
patients with IE correlates with positive expression of GFAP (buffy
particles in the cytoplasm of glial cells), and was observed in the
temporal lobe cortices in both IE patients and the control group
[()TD$FIG]
Fig. 3. GFAP immunoreactivity in the temporal lobe of IE patients by immunohistochemical staining. (A) Faint positive staining in the control illustrates decreased GFAP
expression. Strongly positive staining in the cortex of the temporal lobe of a patient with IE reﬂects increased GFAP expression (buffy particles in the cytoplasm of glial cells).
(B) Immunoﬂuorescence of m-calpain expression in the control and patients with temporal lobe epilepsy. The white arrows indicate positive cells (glial cell) representing
increased m-calpain expression. Scale bars = 75 mm. The data are expressed as mean  SD, and the value of *p < 0.05 is indicated as signiﬁcantly different.
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(Fig. 3). Positive staining for GFAP in this section is brown. The
mean optical densities for the IE group and control group were
0.5482  0.042 and 0.3942  0.038, respectively. There was signiﬁ-
cantly higher expression of GFAP in the temporal lobe cortex of the IE
group compared to the control group (p < 0.05). Immunoﬂuorescence
staining shows positive staining for GFAP in this section as red. The
mean optical densities for the IE group and control group were
0.7338  0.0972 and 0.5923  0.0945, respectively. There was
signiﬁcantly higher expression of GFAP in the temporal lobe cortex
of the IE group compared to the control group (p < 0.05).
3.5. IL-1b, IL-6 and TGF-b1 were upregulated in patients with
intractable epilepsy
Therewerenodifferences inproteinhomogenates levels of IL-10,
IL-12, IL-17a, IFN-g, TNF-a levels between the study groups. Protein
homogenates levels of IL-1b, IL-6 and TGF-b1 were higher and
statistically signiﬁcant in the IE group than in control group (Fig. 4).
3.6. Clinicopathological characteristics of the anterior temporal lobe
in intractable epilepsy
Temporal lobe tissues taken from the control group and from
patients with intractable epilepsy were sliced into 10 mm sections
[()TD$FIG]
Fig. 4. The levels of IL-1b, IL-6 and TGF-b1 were increased in IE patients. Protein
homogenates were extracted from the anterior temporal lobe and the levels of IL-
1b, IL-6 and TGF-b1 were detected simultaneously at 1:20 dilutions. The
concentrations of IL-1b and TGF-b1 in epileptic tissues were signiﬁcantly
greater compared to controls (p < 0.05). The concentration of IL-6 in epileptic
tissues was especially signiﬁcant (p < 0.01). The data are expressed as mean  SD,
and the value of *p < 0.05, **p < 0.01 is indicated as signiﬁcantly different.using a microtome and stained with hematoxylin-eosin. We found
the following four types of pathological changes: neuronal loss,
neuronal degeneration, gliosis and astrocytosis. Fig. 5B, D, and F
are representative of specimens showing neuronal loss, neuronal
degeneration and gliosis. These ﬁndings are consistent with
previous studies of intractable epilepsy revealing neuronal
degeneration and necrosis.18–20
4. Discussion
Since seizures can lead to the impairment of neurons, it can be
surmised that the most important ﬁnding in the pathophysiology
of intractable epilepsy is apoptosis and necrosis of neurons21.
Previous studies have reported that neuronal loss existed in
patients with epilepsy, especially in those with recurrent or status
epilepsy18–20. In our study, we found the following pathological
changes: neuron loss, neuronal degeneration, gliosis and astro-
cytosis. Neuron loss and neuronal degeneration are two, distinct
separate features. Neuronal degeneration is due to hypoxia and
hypoperfusion, but can be reversed if hypoxia and hypoperfusion
are improved. However, neuron loss occurs as a result of
deterioration of neuronal degeneration, and the injured neuron
is swallowed by microglia. Gliosis and astrocytosis have been
conﬁrmed by overexpression of GFAP. Our study results show that
50% of patients had neuronal loss; therefore, we inferred that
neuronal loss, a hallmark of neurodegenerative diseases, plays an
important pathogenic role in the progression of IE.
To our knowledge, this is the ﬁrst time the expression of m-
calpain in the anterior temporal neocortex of patients with IE has
been reported. In our study, we found that the level of m-calpain
and the 145 kDa SBDP corresponds to m-calpain-mediated
cleavage expression in IE brain tissues were up-regulated
phenomenally.
m-calpain, the main subtype of the calpain family which was
found in the central nervous system by Guroff more than 50 years
ago,22 was required in concentrations of 2–80mM Ca2+ for half-
maximal activity. The process of m-calpain activation occurs by an
established progression of events beginning with calcium binding
to the EF-hand structures. Once bound, m-calpain becomes
autocatalytic, cleaving itself on both large and small subunits,
and leaving truncated N-terminals of 76 and 18 kDa, respective-
ly.23 Thus, this process could catalyze the proteolysis involved in
cytoskeletal remodeling, cytokine, cell-cycle regulation, signal
transduction, cell differentiation, embryonic development and
vesicular trafﬁcking.24,25 However, pathological overactivation of
[()TD$FIG]
Fig. 5. Hematoxylin-eosin staining of brain tissue from control and patient group. The control group consisted of temporal lobe samples from 10 patients who underwent
neurosurgical intervention due to brain trauma. Thirty anterior temporal lobe samples were taken from patients with intractable epilepsy. The tissue was sliced into 10 mm
sections using amicrotome and stained with hematoxylin-eosin. The controls are represented by A, C, E. The epileptic anterior temporal lobe samples are represented by B, D,
and F. The white arrows are pointing at neuronal loss (B) and neuronal degeneration (D) and gliosis (F). Scale bars = 100 mm.
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eventually, causes cell death.26
Spectrin is widely distributed throughout the cytoplasm and is
easily accessible for cleavage by different proteases, giving rise to
stable spectrin breakdown products (SBDPs) that can be identied
by immunostaining. It is now known that m-calpain-mediated
breakdown of aII-spectrin creates several aII-spectrin breakdown
products (SBDPs). Caspase-3-mediated cleavage creates 150 and
120 kDa SBDPs, whereas m-calpain creates 150 and 145 SBDPs. In
this study, the cleavage product of m-calpain (including the
150 kDa and 145 kDa spectrin) and the cleavage product of caspase
3 (including the 150 kDa and 120 kDa spectrin) were regulated by
m-calpain. Therefore, this study selected 145 kDa SBDP, instead of
150 kDa, as a marker of increased m-calpain expression. The
145 kDa SBDP corresponds to m-calpain-mediated cleavage was
found to be increased in the patient specimens.
The previous study by Araujo et al.16 had shown that seizures
lead to calpain activation and proteolysis of spectrin in the
hippocampus as a result of KA injection. This clinical ﬁnding shows
that temporal neocortex from intractable epilepsy patients express
raised levels of Bcl-2, Bcl-XL and activated caspase 3.6 Moreover,
during focal cerebral ischemia-reperfusion, m-calpain is an
upstream regulator of caspase 3,27 and has been suggested to be
involved in apoptosis by activating caspase-3 in IE.
Certainly, m-calpain can also injure neurons by other
pathways.m-calpain could regulate cytokines.28–30 While cyto-
kines are associated with pathological changes in intractable
epilepsy.31,32 This clinical ﬁnding shows that marked activation of
microglia and astrocytes and diffuse cell death were observed in
epileptogenic tissue. IL-1beta, IL-8, IL-12p70 and MIP-1beta were
signiﬁcantly increased in the epileptogenic cortex. IL-6 and MCP-1
were signiﬁcantly higher in patients with family history of
epilepsy.31 Their results suggest that active neuroinﬂammation
and marked cellular injury occur in pediatric epilepsy and may
play a common pathogenic role or consequences in childhood
epilepsy of diverse etiologies. In our study, we found that
upregulated expression of IL-1b, IL-6 and TGF-b1 belongs to
inﬂammation markers. Therefore, we theorized thatm-calpain can
cause these pathological results through inﬂammation.
However, several issues need to be considered when inter-
preting the results of this study. Firstly, because of the practical
difﬁculty in obtaining normal human brain specimens, we had to
use structurally normal brain tissue obtained from temporallobectomies performed for the treatment of traumatic brain
injuries as controls. We made a preliminary evaluation of the
control tissues by Western blot analysis to determine whether
expression of m-calpain in brain trauma specimens were accor-
dant. The results show that there is no difference in the expression
of m-calpain among the ﬁve control anterior temporal neocortex
samples which were collected. Recent studies have shown that
structurally normal brain tissue obtained from traumatic brain
injury can be used as controls.33,34 Secondly, m-calpain’s involve-
ment in the pathological process leading to causative or
consequential epileptic seizures remains unclear. Based on the
potential effects of m-calpain on neuronal apoptosis, we hypothe-
size that its upregulationmay play an important pathogenic role in
the progression of IE. However, due to the limitations of the human
study, the abovementioned hypothesis should be further investi-
gated in animal models and in vitro experiments.
In conclusion,m-calpain is upregulated in the anterior temporal
neocortex of patients with IE, which may correlate with
pathological changes in these regions. The biological signiﬁcance
of overexpression of m-calpain warrants further investigation.
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